Product Description
Seletalisib is a novel small-molecule inhibitor of PI3K? that was evaluated in biochemical assays, cellular assays of adaptive and innate immunity, and an in vivo rat model of inflammation.
Mechanisms of Action: PI3K Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: UCB
Company Location:
Company Founding Year: 1928
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Sjogren's Syndrome
Phase 1: Psoriasis|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2015-002900-10 |
2015-002900-10 | P1 |
Completed |
Unknown |
2018-01-23 |
2022-03-13 |
Treatments |
|
NCT02207595 |
UP0021 | P1 |
Completed |
Healthy Volunteers |
2015-02-01 |
2019-03-20 |
Treatments |
|
NCT02303509 |
PS0001 | P1 |
Completed |
Psoriasis |
2014-02-01 |
2019-03-20 |
Treatments |
|
2014-004523-51 |
2014-004523-51 | P2 |
Terminated |
Sjogren's Syndrome |
2017-09-27 |
2022-03-13 |
Treatments |
|
NCT02610543 |
SS0004 | P2 |
Terminated |
Sjogren's Syndrome |
2017-09-07 |
2019-03-20 |
Treatments |
|
2015-005541-30 |
2015-005541-30 | P3 |
Completed |
Unknown |
2018-12-13 |
2022-03-13 |
Treatments |